vTv Therapeutics received a patent allowance for cadisegliatin, an oral therapy for type 1 diabetes, enhancing its innovation protections.
Quiver AI Summary
vTv Therapeutics Inc. announced that the United States Patent and Trademark Office has granted a Notice of Allowance for a patent application related to crystalline forms of salts and co-crystals of its drug cadisegliatin, aimed at treating type 1 diabetes. The patent, effective through 2041, enhances the protection for cadisegliatin, which is being investigated as a first-in-class oral adjunctive therapy to insulin. CEO Paul Sekhri expressed satisfaction with this patent outcome as a key milestone for the company. Cadisegliatin, a liver-selective glucokinase activator, is currently in Phase 3 trials and has received Breakthrough Therapy designation from the FDA, although its safety and efficacy are still under investigation and it may not become commercially available.
Potential Positives
- The issuance of a Notice of Allowance for a patent related to cadisegliatin strengthens the company's intellectual property protection, enhancing its market position.
- The patent term extending through 2041 provides long-term exclusivity for the product, which can lead to potential revenue and investment stability.
- The successful patent application is a significant milestone that demonstrates vTv Therapeutics' commitment to innovation in diabetes treatment.
- Cadisegliatin, with Breakthrough Therapy designation from the FDA and currently in Phase 3 trials, positions the company as a key player in the development of new diabetes treatments.
Potential Negatives
- The safety and efficacy of cadisegliatin have not been established, highlighting the uncertainty of its therapeutic potential.
- There is no guarantee that cadisegliatin will receive health authority approval or become commercially available, which may impact investor confidence.
- The company's focus on a single lead asset, cadisegliatin, may pose significant risks if the product fails to progress successfully through trials or regulatory approval.
FAQ
What is cadisegliatin?
Cadisegliatin (TTP399) is a novel oral glucokinase activator being developed for Type 1 diabetes treatment.
What recent announcement did vTv Therapeutics make?
vTv Therapeutics announced a Notice of Allowance for a patent application for crystalline forms of cadisegliatin.
How long is the patent term for cadisegliatin?
The patent term for cadisegliatin runs through 2041.
What designation has the FDA granted to cadisegliatin?
The FDA has granted cadisegliatin Breakthrough Therapy designation, supporting its clinical investigation.
Is cadisegliatin proven safe and effective?
No, cadisegliatin's safety and efficacy have not yet been established and it is still under investigation.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VTVT Hedge Fund Activity
We have seen 6 institutional investors add shares of $VTVT stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NORTHERN TRUST CORP added 15,626 shares (+inf%) to their portfolio in Q1 2025, for an estimated $270,642
- CONNECTIVE CAPITAL MANAGEMENT, LLC added 9,377 shares (+inf%) to their portfolio in Q1 2025, for an estimated $162,409
- UBS GROUP AG removed 3,472 shares (-46.2%) from their portfolio in Q1 2025, for an estimated $60,135
- JPMORGAN CHASE & CO removed 1,800 shares (-99.8%) from their portfolio in Q1 2025, for an estimated $31,176
- MORGAN STANLEY removed 400 shares (-34.9%) from their portfolio in Q1 2025, for an estimated $6,928
- TOWER RESEARCH CAPITAL LLC (TRC) added 394 shares (+inf%) to their portfolio in Q1 2025, for an estimated $6,824
- ROYAL BANK OF CANADA removed 376 shares (-98.2%) from their portfolio in Q1 2025, for an estimated $6,512
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$VTVT Analyst Ratings
Wall Street analysts have issued reports on $VTVT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 04/09/2025
To track analyst ratings and price targets for $VTVT, check out Quiver Quantitative's $VTVT forecast page.
Full Release
HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cadisegliatin . The patent term runs through 2041.
“We are pleased with the outcome of the prosecution of this patent as it further strengthens the protection around cadisegliatin ,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. “This successful patent application demonstrates our strong commitment to protecting the innovation of our lead asset and is another important milestone for vTv Therapeutics.”
About Cadisegliatin
Cadisegliatin
(TTP399)
is a novel, oral small molecule, liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment for Type 1 diabetes (T1D). In non-clinical studies,
cadisegliatin
, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage.
Cadisegliatin
has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) and is currently being studied in the Phase 3 CATT1 trial.
Cadisegliatin is under investigation and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by
cadisegliatin
, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
[email protected]
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
[email protected]
